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Aims We explored the use of highly purified murine and human pluripotent stem cell (PSC)-derived cardiomyocytes (CMs)
to generate functional bioartificial cardiac tissue (BCT) and investigated the role of fibroblasts, ascorbic acid (AA), and
mechanical stimuli on tissue formation, maturation, and functionality.
Methods
and results
Murine and human embryonic/induced PSC-derived CMs were genetically enriched to generate three-dimensional CM
aggregates, termed cardiac bodies (CBs). Addressing the critical limitation of major CM loss after single-cell dissociation,
non-dissociated CBs were used for BCT generation, which resulted in a structurally and functionally homogenous syn-
cytium. Continuous in situ characterization of BCTs, for 21 days, revealed that three critical factors cooperatively improve
BCT formation and function: both (i) addition of fibroblasts and (ii) ascorbic acid supplementation support extracellular
matrix remodelling and CB fusion, and (iii) increasing static stretch supports sarcomere alignment and CM coupling. All
factors together considerably enhanced the contractility of murine and human BCTs, leading to a so far unparalleled
active tension of 4.4 mN/mm2 in human BCTs using optimized conditions. Finally, advanced protocols were implemen-
ted for the generation of human PSC-derived cardiac tissue using a defined animal-free matrix composition.
Conclusion BCT with contractile forces comparable with native myocardium can be generated from enriched, PSC-derived CMs,
based on a novel concept of tissue formation from non-dissociated cardiac cell aggregates. In combination with the
successful generation of tissue using a defined animal-free matrix, this represents a major step towards clinical applic-
ability of stem cell-based heart tissue for myocardial repair.
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Introduction
Current therapeutic strategies targeting cardiovascular diseases
include the enhancement of endogenous regeneration,1,2 the injection
of single cells,3–5 or the applicationof bioartificial tissueconstructs.6–8
The identification of a suitable cell source is one of the most
critical aspects of myocardial tissue engineering. Pluripotent stem
cells (PSCs), i.e. embryonic stem cells (ESCs),9,10 and induced
PSCs (iPSCs)11,12 hold the capability of differentiating into cells
of all three germ layers, including cardiomyocytes (CMs).13–16
Recent advance in reprogramming technology including generation
of transgene-free iPSCs,17 raised expectations on the clinical
application of iPSCs in the foreseeable future. Engraftment and
long-term survival of iPSC-derived CMs (iPSC–CMs) has been
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demonstrated in small animal hearts already.18–20 However, large
areas of structurally integrated de novo myocardium have not
been observed. Moreover, despite demonstration of electric coup-
ling, the recently observed functional improvements were typically
rather modest and far from restoring healthy heart function in
vivo.4,21,22 To date, the underlying reasons are not entirely clear.
Much likely, the way of surgical delivery is one major limitation
and the transplantation of contractile myocardial patches might
be beneficial in terms of long-term cell retention, survival, and
function. Moreover, and in contrast to cellular therapies, engi-
neered myocardial tissue might enable replacement of scar tissue
after infarction and reconstruction of congenital malformations.
In animal models, functional tissue generated in vitro from
primary cells was demonstrated to support the failing heart.6,7
So far, PSC-based engineered myocardial-like tissue has been
generated almost exclusively using ESC derivatives after cardiac differ-
entiation in embryoid bodies (EBs), which contain non-cardiac cell
types as well,23 including persisting PSCs.18 However, for well-
structured heart tissue without interfering extra-myocardial compo-
nents, and to avoid teratoma formation after transplantation,24
rigorous purification of CMs, and removal of residual PSCs will
be mandatory. Some studies used murine ESC-derived CMs
(ESC-CMs) enriched by Percoll gradient centrifugation to generate
contractile cardiac tissue.25,26 Cardiomyocytes purified from trans-
genic cell lines expressing antibiotic resistance genes under control
of the cardiac a-myosin heavy-chain (a-MHC, MYH6) promoter
were combined with collagen- or fibrin-based matrices,27–29 or with
the thermo-responsive cell sheet technology.30 Recently, Tulloch
et al.31 provided proof-of-concept that tissue engineering protocols
for human ESC–CMs can also be applied to human iPSC–CMs.
Despite recent progress, current stem cell-based engineered
cardiac tissue is certainly not comparable with native heart
tissue, and few studies, only, have reported measurable contraction
forces of engineered cardiac tissue derived from murine25,29 or
human stem cells,23,31 all using undefined animal-derived matrix
components, such as MatrigelTM or GeltrexTM.
In this study, to the best of our knowledge, it is the first time that
the potential of highly purified CMs derived from murine iPSCs,
human ESCs as well as human iPSCs, to produce functional bioar-
tificial cardiac tissue (BCT) is demonstrated. Our study combined
for the first time a new stimulation strategy for tissue maturation
with a novel concept of tissue formation from non-dissociated
cardiac bodies (CBs), together leading to a dramatic increase in
contractile forces, now comparable with native myocardium. In
addition, we implemented a defined animal-free matrix based on
pure human collagen and hyaluronic acid for human stem cell-
based engineered heart tissue, all together representing a major
step towards clinical applicability for myocardial repair.
Methods
Generation and selection of cardiomyocytes
from murine induced pluripotent stem cells
Murine iPSCs were genetically modified to express a ZeocinTM resist-
ance gene under control of the cardiac-specific a-MHC (MYH6) pro-
moter (see Supplementary material online, Figure S1). Cardiac
differentiation was initiated by EB formation in hanging drops.
Antibiotic-mediated selection of CMs from transgenic murine iPSCs
was initiated on differentiation day (dd) 7 by medium supplementation
with 400 mg/mL ZeocinTM (Life Technologies, Darmstadt, Germany),
leading to CM-enriched aggregates termed CBs, which were character-
ized by immuno-staining, quantitative real-time polymerase chain reac-
tion (PCR), patch clamp analysis, and microelectrode arrays (MEAs)
(see Supplementary material online, Figure S2).
Generation and selection of cardiomyocytes
from human embryonic stem cells and
human induced pluripotent stem cells
Human ESCs and human iPSCs were modified to express a neomycin-
resistance gene under control of the MYH6 promoter (see Supple-
mentary material online, Figure S6A and B). For human ESCs, cardiac
differentiation was initiated by spontaneous EB formation in suspension
culture.24 For human iPSCs, EB formation was induced in V-bottom
96-well plates.32 Antibiotic-mediated selection of CMs was started
3 days after first contractions were observed using 200 mg/mL G418
(Sigma-Aldrich, Steinheim, Germany) to generate human PSC-derived
CBs (see Supplementary material online, Figure S6C–G).
Bioartificial cardiac tissue preparation
and cultivation
As described previously, BCT was prepared from a mixture of liquid
collagen type I and MatrigelTM33,34 (or hyaluronic acid) (Dahlmann
et al., in press)35 combined with cells in a volume of 220 mL (see Sup-
plementary material online, Figure S3A). Two strategies for the prepar-
ation of murine BCTs were compared: (i) use of dissociated
iPSC-derived CMs and (ii) direct use of selected CBs for tissue prepar-
ation on dd14, both with different amounts of g-irradiated murine fetal
fibroblasts. Non-selected EBs were used as controls. For human BCTs,
non-dissociated G418-selected human CBs were used with g-irradiated
human foreskin fibroblasts. Tissue constructs were subject to constant
static stress due to fixation at both ends, at a length of 6 mm. Additional
mechanical stretch was applied in a custom-made bioreactor,34 using
either uniaxial cyclic stretch or stepwise growing static stretch (see Sup-
plementary material online, Figure S3B and C). Tissue formation was
monitored microscopically; vital CMs were visualized based on their
high metabolic activity with 50 nM tetramethylrhodamine methyl ester
(TMRM), selectively staining mitochondria-rich cells.36 Direct measure-
ments of active contraction and passive force were performed using
the bioreactor force sensors.34
Gene expression analysis and assessment
of tissue morphology
Gene expression of cells and BCTs was analysed using semi-
quantitative RT–PCR or quantitative real-time PCR after RNA isola-
tion and reverse transcription. Immuno-fluorescence staining was
used to assess protein expression and to analyse the sarcomere
length of CMs within BCTs. Tissue structure and (sub-)cellular organ-
ization was analysed by transmission electron microscopy.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software
(version 5.03 for Windows; GraphPad Software). Values reported
are means and standard errors of the mean. Unless stated otherwise,
data were analysed by two-way analysis of variance (ANOVA), with the
Bonferroni post hoc test for comparison of any two groups; one-way
ANOVA was used for analysis of unrelated groups as shown in
Figures 3C–H, 5, and 7F and G. P ≤ 0.05 were considered significant.
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Results
Efficient genetic selection of
differentiated murine induced pluripotent
stem cell derivatives generates cardiac
bodies composed of functional
cardiomyocytes
Murine iPSCs were genetically modified for antibiotic selection of
CMs based on integration of a ZeocinTM-resistance gene under
control of the cardiac a-MHC (MYH6) promoter (see Supplemen-
tary material online, Figure S1A and B). ZeocinTM was found to effi-
ciently enrich CMs within differentiated EBs, resulting in
TMRMbright contracting CBs within 7 days of selection (see Supple-
mentary material online, Figure S1C–F). Selected CBs represent a
three-dimensional culture of almost pure CMs (.99% cTnT+
cells, see Supplementary material online, Figure S1I and K), and
their functionality was demonstrated by immuno-staining, quantita-
tive real-time PCR, patch clamp analysis, and microelectrode arrays
(MEA) (see Supplementary material online, Figure S2). Action pot-
ential analysis detected mostly ventricle- and pacemaker-like cells
(both 41%) and fewer atrial-like and Purkinje-like CMs (both 9%)
(see Supplementary material online, Figure S2 and Table S3). Non-
genetic selection of murine iPSC–CMs by fluorescence activated
cell sorting (FACS) of TMRMbright cells was also feasible, yet by far
less efficient: ZeocinTM selection of transgenic murine iPSCs
resulted in .100-fold higher cell yields of 1.6+0.3 viable cells/
iPSC (initially inoculated for differentiation) than TMRM-based
sorting (0.013+ 0.005 cell per iPSC) (see Supplementary material
online, Figure S1G–L). Consequently, to obtain sufficient cell
numbers for cardiac tissue engineering, we used the antibiotic selec-
tion approach for all following experiments.
Figure 1 Fibroblasts are essential for bioartificial cardiac tissue formation from murine induced pluripotent stem cell-derived dissociated car-
diomyocytes and whole cardiac bodies. (A) Bioartificial cardiac tissue containing single cell dissociated cardiomyocytes, only, did not consolidate
and tetramethylrhodamine methyl ester fluorescence as indicator of cardiomyocyte viability decreased. (B) Addition of fibroblasts led to rapid
remodelling of the matrix and improved cardiomyocyte survival. (C) a-Myosin heavy-chain ZeoR selected cardiac bodies without fibroblasts
resulted in bioartificial cardiac tissue with incomplete extracellular matrix remodelling (see arrows in magnified image 1), incomplete
cardiac body fusion (see magnified image 2) and lack of stability. (D) a-Myosin heavy-chain ZeoR selected cardiac bodies with 10% fibroblasts
led to efficient cardiac body fusion (see magnified image 3), with long-term survival of actively contracting bioartificial cardiac tissue without
re-emergence of Oct3/4-eGFP+ cells. Scale bar: 1 mm. See also Supplementary material online, Figures S1 and S2 and Movie S1.
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Generation of functionally and
structurally homogenous myocardial
tissue from murine induced pluripotent
stem cell-derived cardiac bodies is
fibroblast dependent
Previous reports demonstrated the importance of fibroblasts for
CM survival, coupling, and generation of functional and well-
structured myocardial tissue.7,28,29 Therefore, murine iPSC–CMs,
enzymatically dissociated into single cells from ZeocinTM-selected
CBs, were mixed with different amounts (0–25%) of mitotically
inactivated murine foetal (embryonic day 13) fibroblasts and a
MatrigelTM/collagen I-based matrix (see Supplementary material
online, Figure S3). As expected from the literature, addition of
fibroblasts was essential for solid tissue formation, and increased
CM metabolism and viability (Figure 1A and B). However, even
with the optimal amount of fibroblasts, the use of single-cell
murine iPSC–CMs sparsely resulted in spontaneously and
Figure 2 Ascorbic acid critically affects murine induced pluripotent stem cell-derived bioartificial cardiac tissue morphology and extracellular
matrix organization. (A) Immuno-fluorescence staining against cTnT (red)/connexin 43 (green) in sections of cardiac body/fibroblast-based
induced pluripotent stem cell-derived bioartificial cardiac tissue cultivated under control conditions (left) or with ascorbic acid (right); ascorbic
acid-treated bioartificial cardiac tissue showed areas with longitudinally arranged (anisotropic) cardiomyocytes with distinct cross-striation (see
upper part). (B) Transmission electron microscopy showed more prominent cell–cell contacts between cardiomyocytes (intercalated discs,
asterisks) in ascorbic acid-treated bioartificial cardiac tissue and improved orientation of sarcomeres (arrowheads). (C) Immuno-fluorescence
staining against collagen type I (red)/titin (green) showed more prominent collagen fibre bundles in the ascorbic acid-treated group. (D) Trans-
mission electron microscopy showed accumulation of collagen in the intracellular space next to cardiomyocytes and more collagen fibrils
(arrowheads) in ascorbic acid-treated bioartificial cardiac tissue. (A) and (C): nuclei stained with DAPI (blue); scale bars: 20 mm. (B) and
(D): scale bars: 1 mm.
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simultaneously contracting tissue constructs, with maximum active
forces between 150 and 500 mN (n ¼ 30; data not shown).
In a novel straightforward approach, we directly used whole CBs
for the preparation of BCT to prevent disruption of pre-formed
functional cell–cell contacts and major CM death. Cardiac bodies
without fibroblast supplementation resulted in the formation of con-
tractile BCTs with CBs fused to some extent, however, with incom-
plete extracellular matrix (ECM) remodelling and consolidation
(Figure 1C and see Supplementary material online, Movie S1) as
well as lack of stability, preventing force measurements. We found
that a fibroblast content between 8 and 17% resulted in efficient
fusion of CBs over time (see Supplementary material online, Movie
S1) and formation of spontaneously and simultaneously contracting
well-organized tissue with high density of viable TMRMbright CMs
after 21 days of cultivation (Figure 1D). A fibroblast content of 10%
generated BCTs with the highest active forces of 0.75+0.06 mN
measured on d21 (see Supplementary material online, Figure S3E)
and therefore was used for all further experiments. In contrast,
the use of non-selected EBs together with fibroblasts resulted in
the formation of disorganized tissue with persistent pluripotent
cells, large cystic outgrowths, and impaired contractility (see Supple-
mentary material online, Figure S3F).
Figure 3 Comprehensive overview on functional and structural parameters of murine induced pluripotent stem cell-derived bioartificial
cardiac tissue. (A) Maximum forces of murine induced pluripotent stem cell-derived bioartificial cardiac tissue from different treatment
groups: C, control; A, ascorbic acid; G, G-stretch; AG, ascorbic acid and G-stretch; maximum contraction forces (Fmax) measured after electrical
pacing (25 V, 5 ms) showed high impact of AA and moderate influence of G-stretch on d14 and d21. (B) Passive forces increased over time (d14
to d21) and were significantly higher after ascorbic acid-treatment and G-stretch. (C) Analysis of bioartificial cardiac tissue sections
immuno-stained against collagen type I showed strong influence of ascorbic acid on fibre width and alignment (in D, given as [1/angle disper-
sion %]), and of G-stretch on alignment only. (E) Numbers of DAPI-stained nuclei per mm2 were significantly increased for ascorbic acid-treated
bioartificial cardiac tissue. (F ) Fluorescence intensities of TMRM in viable bioartificial cardiac tissue were moderately increased with ascorbic
acid and significantly with G-stretch. (G) Both ascorbic acid and G-stretch significantly increased fluorescence intensities of titin staining of fixed
cryosections. (H ) Sarcomere length, determined in cross-striated cardiomyocytes after cardiac troponin T staining, was significantly increased in
G-stretched bioartificial cardiac tissue. All columns are means+ SEM, n ¼ 8–9 for (A) and (B), n ¼ 83–112 for (C), n ¼ 75–90 for (D),
n ¼ 15–20 areas (0.3 mm2) for (E), (F) and (G), n ¼ 77–184 for (H). *P ≤ 0.05; one-way analysis of variance for (C)–(H). See also Supplemen-
tary material online, Figure S3 and Movie S2.
G. Kensah et al.1138
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Ascorbic acid affects murine induced
pluripotent stem cell-derived bioartificial
cardiac tissue morphology and
contractility via changes in extracellular
matrix organization
Ascorbic acid-treated BCTs showed areas with enhanced
sarcomeric organization (Figure 2A) and more CM–CM contacts
(intercalated discs; Figure 2B). Contraction forces at Lmax were sig-
nificantly higher compared with controls (0.97+0.08 vs. 0.62+
0.03 mN on d14 and 1.15+0.11 vs. 0.75+0.06 mN on d21)
(Figure 3A), with a clear Frank–Starling mechanism visible in the
force–preload relation and a significant impact of AA already at
preload ≥0.3 mm (see Supplementary material online, Figure
S4A). In terms of passive forces (stiffness), BCTs treated with AA
showed significantly higher values on d14 (7.36+1.35 vs.
2.94+0.51 mN) and d21 (9.53+1.35 vs. 3.78+ 0.65 mN) com-
pared with untreated controls, both when determined at Lmax
(Figure 3B) and in force–preload measurements, also for
AA-treated control constructs prepared from fibroblasts only
(see Supplementary material online, Figure S4B). At the same
time, the contraction frequency was slightly reduced, without
differences in BCT cross-sectional area after treatment (see
Supplementary material online, Figure S4G and H). Ascorbic acid-
treated BCTs displayed elevated collagen deposition (Figure 2C
and D) with significantly increased collagen I fibre width (21.1+
0.9 vs. 11.0+ 0.4 mm, Figure 3C) and enhanced fibre alignment
compared with controls on d21 (Figure 3D). Numbers of nuclei
were also increased in the AA-treated BCT groups (Figure 3E),
as well as TMRM intensities, measured on d21 (Figure 3F), and
titin intensities of stained CMs in longitudinal sections of BCTs
(Figure 3G). Sarcomere length was not affected by AA treatment
(Figure 3H).
Application of growing stretch affects
murine induced pluripotent stem
cell-derived bioartificial cardiac tissue
morphology and contractility via improved
alignment and cellular maturation
including sarcomere length changes
Common protocols for mechanical stimulation of artificial cardiac
tissue employ cyclic uniaxial stretch (5–10%, 1–2 Hz).7,27,31,34,37
Applied to our CB-based tissue constructs together with AA,
cyclic stretch (10%; 1 Hz) for 7 days neither improved tissue
morphology nor increased active forces [0.77+ 0.07 mN (n ¼ 5)
Figure 4 Growing stretch improves structure and sub-cellular organization of murine induced pluripotent stem cell-derived bioartificial
cardiac tissue. (A) Immuno-fluorescence staining against cTnT (red)/connexin 43 (green) of cardiac body/fibroblast-based murine induced pluri-
potent stem cell-derived bioartificial cardiac tissue cultivated under control conditions (left) or with G-stretch (right; notably both groups
without AA). G-stretched bioartificial cardiac tissue showed large areas with uniform distribution of viable cardiomyocytes and better alignment
along the longitudinal axis of the bioartificial cardiac tissue. Scale bars: 20 mm. (B) Transmission electron microscopy showed improved sarco-
meric organization within CMs on d21 (symbols indicate sarcomere orientation) in cross-sections of G-stretched bioartificial cardiac tissue.
Scale bars: 1 mm. (C ) Immuno-fluorescence staining against cTnT (green) shows broader sarcomeric structures of G-stretched bioartificial
cardiac tissue. Scale bars: 20 mm. (A) and (C) Nuclei stained with DAPI (blue). See also Supplementary material online, Figures S4 and S5.
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vs. 0.97+0.08 mN for static stretch (n ¼ 8)] (see Supplementary
material online, Figure S4J and K).
In an attempt to recapitulate the increasing systolic and diastolic
pressure in the developing embryonic heart,38 growing static
stretch (G-stretch) was applied through stepwise elongation by
200 mm every second day from d7–d21, and led to an improved
formation of elongated tissue from individual CBs (see Supplemen-
tary material online, Figure S4J). At the same time, large areas with
uniform distribution of viable CMs and enhanced alignment along
the longitudinal axis of the BCT (Figure 4A) were observed, to-
gether with improved sarcomeric organization within CMs on
d21 (Figure 4B).
Application of G-stretch improved maximum contraction force
development on d14 and d21, albeit to a lesser extent than in
the AA-treated group (Figure 3A and see Supplementary material
online, Figure S4C). In contrast, passive forces of stretched BCTs
were higher compared with the controls and AA-treated BCTs
(Figure 3B and see Supplementary material online, Figure S4D).
Again, responses to preload in G-stretched CB-based constructs
were recapitulated in G-stretched CM-free fibroblast-based con-
structs (see Supplementary material online, Figure S4D). Notably,
higher forces observed after mechanical stimulation with
G-stretch did not result in elevated gene expression levels for
b-MHC, atrial natriuretic factor (ANF), brain natriuretic peptide,
and a-skeletal actin (Act1a), which are usually associated with a
hypertrophic response39 (see Supplementary material online,
Figure S4L). G-stretch resulted in increased collagen I fibre width
in treated constructs, but to a lesser extent as in the AA-treated
group (Figure 3C); an increase in collagen I fibre alignment was
also detected, although not significant (Figure 3D). Nuclei
Figure 5 Gene expression and electrophysiology of optimized murine induced pluripotent stem cell-derived bioartificial cardiac tissue. (A)
Quantitative real-time polymerase chain reaction analysis of optimized murine induced pluripotent stem cell-derived bioartificial cardiac tissue
on d21 after combined ascorbic acid and G-stretch treatment demonstrated a-myosin heavy-chain, Cx40, Cx45, and collagen type I expression
levels comparable with neonatal mouse heart (nH). Levels of Cx43 and b-myosin heavy chain were significantly lower than in neonatal mouse
heart and argue for a rather embryonic phenotype; also, collagen type III levels were lower than in the heart; adult mouse heart (aH) shown for
comparison; mean+ SD from n ¼ 4–6 with polymerase chain reaction performed in triplicate; #P ≤ 0.05 to nH; §P ≤ 0.05 to aH; one-way
analysis of variance. (B) A TMRM-labelled murine induced pluripotent stem cell-derived bioartificial cardiac tissue (d21) was plated on a micro-
electrode array; scale bar: 1 mm. (C) Spatio-temporal colour-mapping showed the excitation propagation delay in the tissue during spontaneous
contraction. (D) Cardiomyocyte-representative field potential recordings were obtained, and administration of 10 mM isoprenaline (E), 1 mM
lidocaine (F ), and 30 mM quinidine (G) demonstrated physiological drug responsiveness in murine induced pluripotent stem cell-derived bioar-
tificial cardiac tissue.
G. Kensah et al.1140
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numbers remained unchanged (Figure 3E), but TMRM intensity
and titin expression on d21 were significantly higher compared
with the controls (Figure 3F and G). Moreover, and in contrast to
AA-supplementation, treatment with G-stretch resulted in
significantly increased sarcomere lengths within BCTs (Figures 3H
and 4C).
Combined ascorbic acid treatment and
G-stretch lead to functionally optimized
murine induced pluripotent stem
cell-derived bioartificial cardiac tissue
Active contraction forces measured on d14 and d21 showed that
combined treatment with AA and G-stretch during cultivation had
an additional effect on mechanical properties of BCTs, compared
with the untreated control and groups receiving individual treat-
ment only, and resulted in forces of 1.22+ 0.13 on d14 and
1.42+0.09 mN on d21 (Figure 3A), again with a physiological
force–preload relationship (see Supplementary material online,
Figure S4E). Compared with untreated controls, on d21,
maximum active forces almost doubled and passive forces were
about three times higher when measured at Lmax (Figure 3B and
see Supplementary material online, Figure S4F). Murine iPSC-
derived BCT functionality was analysed for up to 5 weeks in
culture, with active forces of 1.27+0.20 mN on d35 (n ¼ 3).
Combined treatment also led to highest passive forces in
fibroblast-only constructs (see Supplementary material online,
Figure S4F).
Combination of both stimuli reflected morphological changes in
constructs treated with one stimulus only. Throughout the whole
tissue, viable CMs were detectable using TMRM labelling during cul-
tivation, as well as after immuno-staining for titin using mid-plane
cryosections of BCTs (see Supplementary material online, Figure
S5A and B). Broad, well-organized, and longitudinally aligned CM
bundles were abundant (comparable with the stretched BCT
group), staining positive for titin, cardiac troponin T, and MLC2v
(see Supplementary material online, Figure S5C–E). Collagen I
fibres were of comparable width as observed in the group treated
with AA (Figure 3C), but showed further increased collagen I align-
ment (Figure 3D). Numbers of nuclei were comparable with the
BCT group treatedwith AA, only (Figure 3E), whilemetabolic activity
visualized by TMRM, titin intensities, and sarcomere length were
comparable with those treated with G-stretch, only (Figure 3F–H).
Optimized murine iPSC-derived BCTs after combined
AA-treatment and G-stretch showed expression levels of a-MHC,
Cx40, Cx45, and collagen type I comparable with neonatal mouse
hearts (Figure 5A). In contrast, levels of b-MHC and collagen type
III were significantly lower than in neonatal heart, as well as Cx43,
which was expressed about 10-fold less. Despite this finding, opti-
mized BCTs displayed synchronized spontaneous contractions
(see Supplementary material online, Movie S2) and efficient CM
coupling was demonstrated using microelectrode-array (MEA)
measurement of whole-mounted BCTs (Figure 5B). We detected a
propagation delay over the whole array (Figure 5C) at a conduction
velocity of 2–3 cm/s, with CM-characteristic field potential (FP)
recordings (Figure 5D); moreover, tissue constructs responded to
cardiotropic drugs such as isoprenaline, lidocaine, and quinidine in
a physiological manner (Figure 5E–G).
Human embryonic stem cell- and induced
pluripotent stem cell-derived cardiac
bodies form bioartificial cardiac tissue
with functional characteristics resembling
native myocardium
We generated transgenic human PSC lines expressing a neomycin
resistance under control of the a-MHC promoter, which led to
the generation of spontaneously beating human CBs (see Supple-
mentary material online, Figure S6A–D and Movie S3). Notably,
human CBs displayed a CM content of 100%, as after seeding of
single cells dissociated from human CBs, immuno-staining con-
firmed every one of these cells to be cTnT-positive (see Supple-
mentary material online, Figure S6E and F). Using our MatrigelTM/
collagen-based protocol with optimized conditions, i.e. addition
of human foreskin fibroblasts, AA-supplementation, and
G-stretch, human CBs efficiently fused into BCTs (see Supplemen-
tary material online, Figure S7A).
Human ESC-derived BCTs showed significant compaction
during cultivation resulting in thin tissue bands with a cross-
sectional area of 0.31+0.11 mm2 on d21 (see Supplementary ma-
terial online, Figure S7B). Both human ESC-derived and human
iPSC-derived BCTs showed longitudinal alignment of CMs and col-
lagen bundles (Figure 6A and B) with viable CMs throughout the
whole construct (see Supplementary material online, Figure S8A).
Within BCTs, human stem cell-derived CMs expressed Nkx2.5
and Cx43 (Figure 6C and D); they displayed clear cross-striation
and alignment of sarcomers (see Supplementary material online,
Figure S7J and K). Besides the relatively mature phenotype observed
for most CM within BCTs, some cells remain active in the cell cycle
as shown by confocal microscopy analysis of immuno-staining for
2.5% Ki-67+/Nkx2.5+ CM within human iPSC-derived BCTs (see
Supplementary material online, Figure S9A), and 3.6+ 0.6%
Ki-67+/Nkx2.5+ CM in human ESC-derived BCTs (not shown). Im-
portantly, we did not observe residual expression of the pluripo-
tency marker Oct3/4 in human ESC-derived BCTs. In contrast,
BCTs showed strong expression of cardiac markers Nkx2.5,
ANF, MLC2v, cTnT, a-MHC, and b-MHC, as well as CM-specific
ion-channel proteins human Ether-a`-go-go Related Gene,
SCN5A, and CACNA1C, both on d8 and d22 (see Supplementary
material online, Figure S6G). For optimized human ESC-derived
BCTs after combined AA and G-stretch treatment, quantitative
real-time PCR analysis demonstrated increasing expression levels
of the ventricular myosin light-chain isoform MLC2v (in relation
to MLC2a) and the ion-channel subunit Kir2.1 (mediating the
inward rectifier potassium current IK1), while levels of the ANF
did not change significantly over time (Figure 7A–C). Spontaneous
contractions were observed both in human iPSC- and human ESC-
derived BCTs (see Supplementary material online, Movie S4), the
latter with a frequency of up to 54.4+3.6 bpm on d21 after com-
bined treatment with AA and G-stretch (see Supplementary ma-
terial online, Figure S7G). Efficient CM coupling was
demonstrated using MEA measurement of whole-mounted BCTs
(Figure 7D) with a conduction velocity of up to 4.9 cm/s. MEA
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recordings showed an increase in contraction frequency in re-
sponse to the b-adrenergic agonist isoprenaline (Figure 7E),
which was quantified in bioreactor measurements of BCT
contractility at a low Ca2+ concentration of 0.6 mM, demonstrating
significantly increased frequencies of 199+51% of baseline levels
(Figure 7F). Moreover, following isoprenaline addition, active forces
Figure 6 Human pluripotent stem cell-derived bioartificial cardiac tissue shows high density of cardiomyocytes and well-structured tissue
morphology. (A) Both in sections of human embryonic stem cell-derived and human induced pluripotent stem cell-derived bioartificial
cardiac tissue cultivated with ascorbic acid and G-stretch, longitudinally arranged (anisotropic) cardiomyocytes with distinct cross-striation
were detected by immuno-fluorescence staining against a-sarcomeric actinin (green)/vimentin (red) on d21 and d28, respectively. (B) Both
displayed similar cell and matrix organization with longitudinal alignment of collagen type I bundles (red) and cardiomyocytes visualized by stain-
ing titin (green). (C ) Bioartificial cardiac tissue displayed a high density of viable cardiomyocytes staining positive for Nkx2.5 (red)/titin (green);
(D) with expression of Cx43 (green) localized between cardiomyocytes (positive for cTnT, red). Nuclei stained with DAPI (blue); scale bars: (A)
50 mm, (B), (C), and (D) 100 mm; for insets¼10 mm. See also Supplementary material online, Figures S7 and S8.
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were significantly increased to 147+22% (Figure 7G). Subsequent
addition of the muscarinergic agonist carbachol (10 mM) reduced
both contraction frequency and active forces (Figure 7F and G).
Functionality of human iPSC-derived and human ESC-derived
BCTs was further demonstrated by the assessment of active and
passive forces in response to increasing preload (Figure 8A and B).
For d21 human ESC-derived BCTs, combined AA-supplementation
and G-stretch resulted in higher maximum active forces of 1.37+
0.18 vs. 0.78+ 0.17 mN for the untreated control (Figure 8C and
E). Passive forces were significantly increased on d14 (8.50+1.71
vs. 3.30+1.54 mN), both when determined at Lmax (Figure 8D)
and in force–preload measurements (Figure 8F), and tended to be
higher on d21, although not reaching statistical significance
(4.66+0.64 vs. 1.57+0.52 mN). In addition, to replace the un-
defined animal-derived MatrigelTM, we used a defined matrix (DM)
for human BCTs, which is based on human collagen type I and in
situ cross-linking hyaluronic acid hydrogel and devoid of any animal-
derived components (Dahlmann et al., in press).35 Using optimized
conditions for tissue preparation and maturation, our DM–BCTs
yielded similar forces per construct as observed using MatrigelTM
(see Supplementary material online, Figure S7C–F and L). Finally,
details of an original force recording of a human iPSC-derived
BCT are presented in Supplementary material online, Figure S9B–D.
Discussion
In this study, we demonstrate rigorous purification of PSC-derived
CMs with transgene-based antibiotic selection.27,29 We describe
for the first time that pure CMs in autonomously contracting
highly defined units, i.e. CBs, can be used directly, i.e. without
harmful disruption of pre-formed functional cell–cell contacts,
for the generation of three-dimensional BCT with physiological
properties. In our hands, the use of ZeocinTM selection-based
single cell-dissociated murine iPSC–CMs sparsely led to contract-
ing tissue with reduced cell viability and active forces.
As indicated by the connexin expression pattern, our CBs have
to be considered as artificial three-dimensional monocultures of
pure CMs at an early developmental stage. We hypothesized
Figure 7 Optimized human pluripotent stem cell-derived bioartificial cardiac tissue show maturation towards a ventricular phenotype. Quan-
titative real-time polymerase chain reaction analysis of optimized human embryonic stem cell-derived bioartificial cardiac tissue on d7, d14, and
d21 showed (A) increasing expression levels of the ventricular myosin light-chain isoform MLC2v in relation to MLC2a after combined ascorbic
acid and G-stretch treatment (AG, black bars) but not in untreated controls (C, grey bars), and (B) increasing expression levels of Kir2.1 in both
groups over time, while (C) expression levels of atrial natriuretic factor did not change significantly. Expression levels of human cardiac bodies
on d23 of differentiation are shown for comparison, representing the starting material for bioartificial cardiac tissue preparation; mean+ SD
(n ¼ 3 with polymerase chain reaction performed in triplicate; #P ≤ 0.05 to cardiac bodies; *P ≤ 0.05 between indicated groups). (D) Micro-
electrode array-based spatio-temporal colour mapping showed the excitation propagation delay in the tissue during spontaneous contraction of
a human embryonic stem cell-derived bioartificial cardiac tissue on d22. (E) Cardiomyocyte-representative field potential recordings were
obtained (black, see squares), and administration of 10 mM isoprenaline demonstrated physiological drug responsiveness (red, see circles).
See also Supplementary material online, Movie S4. Noradrenaline was added between d7 and d21 to all ascorbic acid and G-stretch-treated
MatrigelTM-bioartificial cardiac tissue. Functionality of human embryonic stem cell-derived bioartificial cardiac tissue was further demonstrated
by assessment of spontaneous contraction frequencies (F) and active forces (G), both at 0.6 mM Ca2+ and in response to 0.1 mM isoprenaline
(Iso) and 10 mM carbachol (CCh); values are given normalized to un-stimulated baseline levels (¼100%) as mean+ SD for n ¼ 6; *P ≤ 0.05;
one-way analysis of variance.
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that these immature myocytes, just like in the embryonic heart,
may display a high degree of plasticity and migratory capacity to
enable CB fusion and substantial remodelling towards structural
and functional homogenous cardiac tissue. Indeed, CB fusion
resulted in a functional syncytium. Notably, the direct use of un-
dissociated CBs was possible only because the EB-based selection
procedure was optimized to eliminate any residual Oct3/4-eGFP+
PSCs in CBs and BCTs, thus preventing the formation of disorga-
nized non-cardiac tissue components typically observed using
non-selected EBs.
In situ characterization of CB-based murine iPSC-derived
BCTs in a bioreactor for 21 days allowed us to identify critical
effectors of tissue formation and functionality and their
mechanisms of action. It has been reported for isolated
primary rat heart cells7 and dissociated murine ESC-derived
CMs that the presence of a certain proportion of fibroblasts is
essential for cell alignment40 and the generation of engineered
heart tissue.29 We could confirm these findings for murine iPSC-
derived CMs. Moreover, we now demonstrate that fibroblast-
driven ECM formation and remodelling does not only support
interconnection of adjacent individual myocytes. As suggested
by Supplementary material online Movie S1, it was also essential
to overcome the functional and structural isolation of initially
distant CBs, and was required for final fusion of individual CBs
into homogenous and stable BCTs with considerably higher
forces.
Figure 8 Optimized human pluripotent stem cell-derived bioartificial cardiac tissue shows increased active and passive contraction forces.
Functionality of human induced pluripotent stem cell-derived (A) and human embryonic stem cell-derived bioartificial cardiac tissue (B) was
demonstrated by assessment of active and passive contraction forces upon electrical pacing in response to increasing preload at d28 and
d21, respectively. (C) Maximum contraction forces of human embryonic stem cell-derived bioartificial cardiac tissue from different treatment
groups: C, control, and AG, ascorbic acid and G-stretch, measured after electrical pacing (25 V, 10 ms) showed increased forces after the com-
bined treatment on d10, d14, and d21. (D) With AG-treatment, human embryonic stem cell-derived bioartificial cardiac tissue passive forces
increased over time from d10 to d14, and were significantly higher than in untreated controls. (E) Preload was increased stepwise to determine
maximum active force (Fmax) for human embryonic stem cell-derived bioartificial cardiac tissue treated with AG (full squares), compared with
untreated controls (open squares) on d14; both curves reflect the Frank–Starling mechanism of increasing force–preload relation seen in native
heart muscle. (F ) Similarly, d14 passive force–preload relation in human embryonic stem cell-derived bioartificial cardiac tissue was significantly
higher in the AG group (full squares) vs. controls (open squares). Symbols represent mean baseline force+ SEM; (C) and (D) n ¼ 3–7 per
group; (E) and (F) n ¼ 4–7 per group. *P ≤ 0.05 between indicated groups; #P ≤ 0.05 for all indicated data points compared with respective
control at the same preload. See also Supplementary material online, Figures S7 and S9.
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As a further measure to improve functionality of iPSC–BCTs,
we evaluated medium supplementation with AA. Ascorbic acid is
well known for its radical scavenger properties and regulatory
effects both on pro-collagen expression and collagen post-
transcriptional modification.41 It can also act as a pro-oxidant in dif-
ferentiating mouse ESCs42 and improve cardiac differentiation and
maturation as well as CM progenitor cell proliferation.43 In addition
to the positive effect of AA on ECM and cellular organization
within BCTs, our data provide evidence for direct effects on CM
maturation or survival. This was demonstrated by increased colla-
gen fibre width and alignment, adding to the passive forces, as well
as higher nuclei numbers, metabolic activity, and titin protein levels
of CMs, altogether resulting in higher active contraction and
passive forces for AA-treated BCTs.
Another critical factor for tissue functionality identified in this
study is increasing mechanical stimulation. Common protocols
for mechanical stimulation of artificial cardiac tissue use invariant
cyclic uni-axial stretch (5–10%, 1–2 Hz), which is usually accom-
panied by a hypertrophic response.7,25,27,34 While uni-axial cyclic
stretch might interfere with spontaneous isotropic contractions
of early CMs within CBs, growing uniform stretch could be bene-
ficial to recapitulate the physiological conditions of the growing
embryonic myocardium with increasing systolic and diastolic pres-
sure37 and continuously increasing contractile force.44 Growing
static stretch has been shown to induce rabbit skeletal muscle
growth in vivo;45 however, it has not been applied in cardiac
tissue engineering before.
In our study, mechanical stimulation with growing static stretch
led to significantly higher forces when compared with invariant
cyclic stretch and consequently was used in all further experi-
ments. On a structural level, G-stretch had a significant impact
on CM viability and metabolism as demonstrated by increased
TMRM fluorescence. It induced improved sarcomere alignment
and increased sarcomere length within stretched BCTs. This is
similar to embryonic heart development; here, an increase in myo-
fibre density and improvement in the alignment of myocytes was
described as additional underlying mechanisms of an increase in
contraction forces, which cannot be ascribed to the accumulation
of contractile proteins (MHC) only.44 Also, in heart development,
regional myofibre alignment is observed preferentially at sites of
regional orthotropic epicardial wall strain46 and higher forces
from aligned tissue generated in vitro have been demonstrated.47
The above positive effects of fibroblast addition, AA supplemen-
tation, and growing mechanical stretch were successfully combined
for optimized murine iPSC-derived BCTs with improved function-
ality. The molecular mechanisms supporting increased force devel-
opment most probably involve a positive feedback loop of
cell-mediated matrix synthesis, remodelling, and organization on
the one hand, and matrix-mediated effects on cellular viability, me-
tabolism, ultra-structure and contractility on the other hand, as
proposed by Discher et al.48 Although Cx43 expression levels in
these optimized BCTs were significantly lower than in the native
heart, MEA measurement demonstrated efficient coupling, pre-
sumably with a major contribution of Cx45 gap junctions, leading
to synchronized contractions of whole BCTs.
Our data demonstrate that this novel approach can be extended
to human iPSCs and ESCs for the in vitro generation of well-
structured myocardial-like tissue. Moreover, as CM maturation
can be assessed based on the expression level of MLC2v49 and
Kir2.1,50,51 we conclude that our optimized human ESC-derived
BCTs showed maturation towards a ventricular phenotype. Func-
tionality was demonstrated both for murine and human BCTs by
direct force measurement. So far, no data have been available on
the contraction forces of murine iPSC-derived BCT. However,
active forces for murine iPSC–BCTs obtained with our novel
CB-based protocols are of the same magnitude as achieved by
state-of-the-art cardiac tissue engineered constructs based on iso-
lated primary neonatal rat CMs using similar cell numbers per
volume7,34,52 or murine ESC-derived CMs.29
With active contraction forces of the BCT of up to 1.37+
0.18 mN at a cross-sectional area of 0.31+0.11 mm2 on d21,
our human BCTs reached a maximum active tension of 4.4 mN/
mm2. Notably, this is 37- and 55-fold higher than reported recently
for human ESC-derived tissue generated from non-enriched23 or
partially enriched CMs,31 respectively. These data clearly confirm
the need for vigorous CM purification. Human DM–BCTs based
on human collagen type I and hyaluronic acid, which are devoid
of any animal-derived components, displayed active contraction
forces comparable with MatrigelTM-based constructs.
Active contraction forces of myocardial strips isolated from
native human ventricles have been determined to range between
14.5+ 4.4 and 22.8+1.4 mN/mm2 for healthy donors.53,54
Therefore, maximum forces of our human BCTs are only 3- to
5-fold lower than active forces reported for native human
myocardium.
Human BCT contractility was modulated in response to iso-
prenaline with a positive chronotropic effect and in response to
carbachol with a negative chronotropic effect, demonstrating func-
tional b-adrenergic and muscarinergic receptor systems.23 For our
optimized human BCTs, these effects were even more pro-
nounced than demonstrated before for human PSC-derived
CMs55 and engineered heart tissue.23 Moreover, we were able
to show a significant positive inotropic effect of isoprenaline on
human BCTs, arguing in favour of the existence of a functional
sarcoplasmic reticulum, which is a hallmark of mature myocar-
dium.56 This inotropic effect was absent or found less pronounced
in previous studies on human PSC-derived CMs55 or engineered
heart tissue,23 respectively.
We conclude that highly efficient enrichment of murine and
human PSC-derived CMs in CBs allowed for successful cardiac
tissue formation and maturation, with so far unparalleled contrac-
tion forces. Cardiac tissue patches with improved functionality
should be valuable for high throughput pharmacological testing
and iPSC-based cardiac disease modelling.57 They provide repro-
ducible three-dimensional cell culture models, and in combination
with suitable read-out systems such as our miniaturized multi-
modal bioreactor, they enable the investigation of certain mechan-
istic aspects of disease and regeneration already in vitro. For future
clinical application, genetic selection of PSC-derived CMs needs to
be further optimized; in this regard, the use of zinc-finger
nucleases, which have been designed to target ‘safe harbour
sites’ such as the adeno-associated virus integration site 1 locus
in human ESCs and iPSCs,58 appears to be a promising approach
for controlled and safe insertion of selection markers.
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Alternatively, the recently described FACS sorting using surface
markers such as signal regulatory protein alpha might offer a non-
genetic CM selection strategy.59 Moreover, for future clinical appli-
cation, it might soon be possible to address the problem of insuf-
ficient vascularization of in vitro generated working myocardium
through the application of MSCs, as proposed by Tulloch et al.,31
or more likely, cardiovascular progenitor cell types selectable
from iPSCs as shown by Mauritz et al.18 Recently, Zwi-Dantsis
et al.5 demonstrated the generation of functional CMs even from
advanced heart failure patients’ iPSCs. Now, our advanced proto-
cols yielded human PSC-derived BCT with contractile forces com-
parable with native myocardium. In addition, our study
demonstrated the implementation of a defined animal-free
matrix based on pure human collagen and hyaluronic acid and
therefore might represent a major step towards clinical applicabil-
ity of stem cell-based engineered heart tissue for myocardial repair.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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